Market Place
Sourcing Support
Algernon Reports 93% Cough Suppression With Ifenprodil
16 Jul 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent
11 Jan 2024 //
GLOBENEWSWIRE
Algernon to Present Phase 2 Ifenprodil Cough Data at Conference
06 Jun 2023 //
GLOBENEWSWIRE
Algernon Announces Plans for 180 Patient Ph 2b Chronic Cough Study of Ifenprodil
09 Jan 2023 //
GLOBENEWSWIRE
Algernon Receives U.S. FDA Orphan Drug Designation for Ifenprodil
05 Dec 2022 //
GLOBENEWSWIRE
FDA grants orphan drug designation to Algernon`s ifenprodil, exclusivity unclear
05 Dec 2022 //
ENDPTS
Algernon Files for Orphan Designation with the U.S. FDA for Ifenprodil
19 Sep 2022 //
GLOBENEWSWIRE
Algernon Reports +ve Results from Full Data Set of its Ph2 Study of Ifenprodil
01 Sep 2022 //
GLOBENEWSWIRE
Algernon Pharma Reports Additional Positive Data From PII Study of Ifenprodil
28 Jul 2022 //
GLOBENEWSWIRE
Algernon Pharma Hits Co-Primary Endpoint in PII Study of Ifenprodil for IPF
19 Jul 2022 //
GLOBENEWSWIRE
Algernon Pharma Announces Issuance of Patent for Ifenprodil for IPF
22 Jun 2022 //
GLOBENEWSWIRE
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil
21 Jun 2022 //
GLOBENEWSWIRE
Algernon Completes Enrollment in Phase 2 Study of Ifenprodil
04 Feb 2022 //
GLOBENEWSWIRE
Algernon Pharma Announces Notice of Allowance for Ifenprodil Patent Application
28 Jan 2022 //
GLOBENEWSWIRE
Algernon receives positive FDA feedback on Phase IIb chronic cough trial
18 Jan 2022 //
CLINICALTRIALSARENA
Algernon Receives Positive Feedback from FDA for Phase 1 Ifenprodil SCL Cancer
24 Nov 2021 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil
08 Oct 2021 //
GLOBENEWSWIRE
Algernon Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study
11 May 2021 //
GLOBENEWSWIRE
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request
08 Apr 2021 //
GLOBENEWSWIRE
Algernon to consider lung scarring as additional endpoint for Covid-19 trial
11 Feb 2021 //
PHARMACEUTICAL-TECHNOLOGY
Algernon Pharmaceuticals Provides Year End Summary of Key Activities
30 Dec 2020 //
GLOBENEWSWIRE
Algernon Announces Last Patient Out in Ph 2b/3 Human Study of Ifenprodil
23 Dec 2020 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Last Patient Out in Multinational Ph 2b/3
23 Dec 2020 //
GLOBENEWSWIRE
Algernon Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil
15 Dec 2020 //
GLOBENEWSWIRE
Algernon completes patient enrollment in phase 2b/3 study of Ifenprodil
02 Dec 2020 //
PHARMABIZ
Algernon wins Data & Safety Monitoring Board approval Ph2b/3 study of Ifenprodil
30 Oct 2020 //
PROACTIVEINVESTOR
Algernon Announces Enrollment of 100 Patients inHuman Study of Ifenprodil
29 Sep 2020 //
GLOBENEWSWIRE
Algernon Enrolled 50th Patient in Multinational 2b/3 Human Study of Ifenprodil
02 Sep 2020 //
GLOBENEWSWIRE
Algernon Announces Enrollment of First U.S. Patient in Phase 2b/3 Human Study
13 Aug 2020 //
GLOBENEWSWIRE
Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil
05 Aug 2020 //
GLOBENEWSWIRE
Algernon highlights UT Dallas research study identifying Ifenprodil a possible
24 Jul 2020 //
PHARMABIZ
Algernon highlights UT Dallas research study Ifenprodil as a possible COVID-19
22 Jul 2020 //
PHARMABIZ
Algernon Announces First U.S. Trial Ph 2b/3 Human Study of Ifenprodil
16 Jul 2020 //
GLOBENEWSWIRE
Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough
07 Jul 2020 //
GLOBENEWSWIRE
Algernon gets ethics approval for Ifenprodil’s Covid-19 trial in US
25 Jun 2020 //
CLINICALTRIALSARENA
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study
04 Jun 2020 //
GLOBENEWSWIRE
Algernon seeks ethics approval for Covid-19 trials in Australia
18 May 2020 //
CLINICALTRIALSARENA
Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF
06 May 2020 //
GLOBENEWSWIRE
Algernon re-purposes Ifenprodil drug against COVID-19
03 May 2020 //
BIOSPECTRUMASIA
Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Ph 2b/3
29 Apr 2020 //
GLOBENEWSWIRE
Algernon`s receives South Korean regulatory approval to ph2 COVID-19 Ifenprodil
26 Apr 2020 //
PHATMABIZ
Algernon Receives Positive Feedback from U.S. FDA for New Ifenprodil
15 Apr 2020 //
GLOBENEWSWIRE
Algernon Receives Positive Feedback from USFDA for Ifenprodil COVID-19 Trial
13 Apr 2020 //
GLOBENEWSWIRE
Algernon Appoints U.S. Company for cGMP Manufacturing of NP-120 (Ifenprodil)
23 Mar 2020 //
YAHOO
Algernon Appoints Novotech as CRO For Phase 2 Coronavirus Ifenprodil Trial
20 Mar 2020 //
GLOBENEWSWIRE
